| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 79 | 2025 | 457 | 17.580 |
Why?
|
| Substance-Related Disorders | 80 | 2025 | 687 | 11.690 |
Why?
|
| Buprenorphine | 35 | 2025 | 182 | 9.130 |
Why?
|
| Opiate Substitution Treatment | 37 | 2025 | 188 | 6.790 |
Why?
|
| Narcotic Antagonists | 30 | 2025 | 121 | 6.680 |
Why?
|
| Substance Abuse Treatment Centers | 34 | 2019 | 104 | 6.180 |
Why?
|
| Prisoners | 32 | 2025 | 151 | 5.950 |
Why?
|
| Drug Overdose | 18 | 2025 | 126 | 5.410 |
Why?
|
| Naltrexone | 23 | 2025 | 77 | 5.370 |
Why?
|
| Substance Abuse, Intravenous | 28 | 2024 | 75 | 4.650 |
Why?
|
| Rural Population | 18 | 2025 | 188 | 4.140 |
Why?
|
| Alcoholism | 20 | 2022 | 310 | 3.750 |
Why?
|
| Analgesics, Opioid | 27 | 2025 | 491 | 3.720 |
Why?
|
| Hepatitis C | 9 | 2024 | 143 | 3.630 |
Why?
|
| Methadone | 32 | 2025 | 127 | 3.520 |
Why?
|
| HIV Infections | 22 | 2025 | 915 | 3.500 |
Why?
|
| Patient Protection and Affordable Care Act | 10 | 2019 | 46 | 3.130 |
Why?
|
| Health Services Accessibility | 18 | 2025 | 527 | 3.110 |
Why?
|
| Humans | 268 | 2025 | 59566 | 2.790 |
Why?
|
| Medicaid | 10 | 2025 | 353 | 2.710 |
Why?
|
| Adult | 131 | 2025 | 15733 | 2.400 |
Why?
|
| United States | 80 | 2025 | 7440 | 2.360 |
Why?
|
| Insurance Coverage | 8 | 2025 | 99 | 2.300 |
Why?
|
| Criminal Law | 9 | 2018 | 70 | 2.220 |
Why?
|
| Male | 159 | 2025 | 27847 | 1.970 |
Why?
|
| Female | 158 | 2025 | 30837 | 1.960 |
Why?
|
| Patient Acceptance of Health Care | 11 | 2025 | 456 | 1.800 |
Why?
|
| Prisons | 12 | 2024 | 105 | 1.770 |
Why?
|
| Drug Users | 7 | 2025 | 28 | 1.690 |
Why?
|
| Health Policy | 5 | 2024 | 177 | 1.680 |
Why?
|
| Delayed-Action Preparations | 11 | 2024 | 111 | 1.670 |
Why?
|
| Alcohol Drinking | 11 | 2022 | 291 | 1.630 |
Why?
|
| Patient-Centered Care | 4 | 2020 | 246 | 1.550 |
Why?
|
| Neonatal Abstinence Syndrome | 4 | 2020 | 33 | 1.520 |
Why?
|
| Primary Health Care | 14 | 2017 | 651 | 1.520 |
Why?
|
| Ambulatory Care | 11 | 2021 | 305 | 1.460 |
Why?
|
| Needle-Exchange Programs | 10 | 2024 | 15 | 1.380 |
Why?
|
| Needle Sharing | 6 | 2024 | 13 | 1.340 |
Why?
|
| Emergency Service, Hospital | 9 | 2022 | 1024 | 1.330 |
Why?
|
| Middle Aged | 76 | 2025 | 16384 | 1.300 |
Why?
|
| Criminals | 7 | 2018 | 53 | 1.300 |
Why?
|
| Secondary Prevention | 9 | 2017 | 153 | 1.260 |
Why?
|
| State Government | 3 | 2019 | 29 | 1.260 |
Why?
|
| Continuity of Patient Care | 6 | 2017 | 170 | 1.210 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2023 | 693 | 1.200 |
Why?
|
| Mass Screening | 11 | 2023 | 649 | 1.190 |
Why?
|
| Narcotics | 7 | 2012 | 50 | 1.180 |
Why?
|
| Referral and Consultation | 9 | 2025 | 405 | 1.160 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2015 | 112 | 1.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2024 | 726 | 1.090 |
Why?
|
| Cross-Sectional Studies | 28 | 2025 | 2386 | 1.080 |
Why?
|
| Cataract Extraction | 3 | 2011 | 34 | 1.040 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2024 | 119 | 1.040 |
Why?
|
| Massachusetts | 18 | 2024 | 2025 | 1.040 |
Why?
|
| Telemedicine | 2 | 2024 | 311 | 1.020 |
Why?
|
| Hepacivirus | 5 | 2024 | 140 | 0.980 |
Why?
|
| New England | 9 | 2024 | 267 | 0.960 |
Why?
|
| Medication Adherence | 2 | 2017 | 241 | 0.950 |
Why?
|
| Attitude of Health Personnel | 8 | 2024 | 552 | 0.930 |
Why?
|
| Delivery of Health Care | 4 | 2020 | 413 | 0.930 |
Why?
|
| Postoperative Complications | 8 | 2011 | 1208 | 0.920 |
Why?
|
| Mothers | 6 | 2023 | 258 | 0.890 |
Why?
|
| Recidivism | 2 | 2022 | 26 | 0.880 |
Why?
|
| Behavior, Addictive | 3 | 2014 | 72 | 0.880 |
Why?
|
| Surveys and Questionnaires | 24 | 2025 | 2519 | 0.870 |
Why?
|
| Fentanyl | 1 | 2024 | 73 | 0.870 |
Why?
|
| Qualitative Research | 9 | 2024 | 619 | 0.860 |
Why?
|
| Sexual Partners | 5 | 2013 | 75 | 0.830 |
Why?
|
| Early Medical Intervention | 2 | 2020 | 17 | 0.820 |
Why?
|
| Health Services Needs and Demand | 9 | 2015 | 203 | 0.820 |
Why?
|
| Behavior Therapy | 3 | 2016 | 161 | 0.820 |
Why?
|
| Pharmacies | 1 | 2023 | 34 | 0.800 |
Why?
|
| Population Surveillance | 3 | 2019 | 195 | 0.770 |
Why?
|
| Counseling | 8 | 2021 | 351 | 0.770 |
Why?
|
| Inservice Training | 2 | 2017 | 81 | 0.760 |
Why?
|
| Smoking Cessation | 7 | 2016 | 541 | 0.760 |
Why?
|
| Injections, Intramuscular | 6 | 2020 | 67 | 0.750 |
Why?
|
| Harm Reduction | 3 | 2024 | 29 | 0.740 |
Why?
|
| Naloxone | 6 | 2023 | 57 | 0.730 |
Why?
|
| Drug Monitoring | 2 | 2012 | 115 | 0.730 |
Why?
|
| Substance Abuse Detection | 5 | 2009 | 44 | 0.720 |
Why?
|
| Tobacco Use Disorder | 4 | 2014 | 243 | 0.720 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 25 | 0.710 |
Why?
|
| Sleep Wake Disorders | 3 | 2008 | 65 | 0.690 |
Why?
|
| Sexual Behavior | 8 | 2025 | 189 | 0.680 |
Why?
|
| Interinstitutional Relations | 2 | 2016 | 37 | 0.680 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 86 | 0.680 |
Why?
|
| Alcohol-Related Disorders | 3 | 2021 | 35 | 0.670 |
Why?
|
| Hospitalization | 8 | 2025 | 1296 | 0.670 |
Why?
|
| Parents | 2 | 2023 | 369 | 0.660 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 330 | 0.660 |
Why?
|
| Infant Health | 1 | 2019 | 2 | 0.650 |
Why?
|
| Maternal Health | 1 | 2019 | 15 | 0.650 |
Why?
|
| Surgical Procedures, Operative | 3 | 2012 | 137 | 0.640 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2019 | 19 | 0.640 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 76 | 0.640 |
Why?
|
| Patient Dropouts | 5 | 2007 | 47 | 0.630 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2019 | 4 | 0.630 |
Why?
|
| Epidemics | 1 | 2019 | 22 | 0.630 |
Why?
|
| Financing, Government | 1 | 2019 | 30 | 0.630 |
Why?
|
| Family Practice | 7 | 2005 | 208 | 0.620 |
Why?
|
| Young Adult | 16 | 2024 | 4285 | 0.620 |
Why?
|
| Fear | 3 | 2024 | 64 | 0.610 |
Why?
|
| Community Health Services | 4 | 2016 | 120 | 0.610 |
Why?
|
| HIV Seropositivity | 7 | 2012 | 82 | 0.600 |
Why?
|
| Veterans | 7 | 2014 | 728 | 0.600 |
Why?
|
| Health Status | 5 | 2022 | 426 | 0.600 |
Why?
|
| Cooperative Behavior | 4 | 2024 | 210 | 0.570 |
Why?
|
| Government Programs | 1 | 2017 | 20 | 0.570 |
Why?
|
| Multivariate Analysis | 13 | 2024 | 905 | 0.570 |
Why?
|
| Rhode Island | 10 | 2013 | 98 | 0.570 |
Why?
|
| Heroin Dependence | 5 | 2012 | 22 | 0.570 |
Why?
|
| Models, Statistical | 3 | 2016 | 299 | 0.570 |
Why?
|
| Quality of Life | 5 | 2020 | 1139 | 0.560 |
Why?
|
| Aged | 40 | 2024 | 13459 | 0.560 |
Why?
|
| Quality Assurance, Health Care | 2 | 2016 | 250 | 0.540 |
Why?
|
| General Surgery | 5 | 2001 | 194 | 0.540 |
Why?
|
| Patient Compliance | 7 | 2018 | 350 | 0.540 |
Why?
|
| Informed Consent | 5 | 2018 | 138 | 0.540 |
Why?
|
| Retrospective Studies | 21 | 2024 | 6113 | 0.530 |
Why?
|
| Politics | 1 | 2017 | 32 | 0.530 |
Why?
|
| Law Enforcement | 2 | 2013 | 24 | 0.520 |
Why?
|
| Public Health | 2 | 2017 | 176 | 0.520 |
Why?
|
| Data Collection | 12 | 2023 | 374 | 0.520 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 5138 | 0.510 |
Why?
|
| Crime | 3 | 2012 | 50 | 0.510 |
Why?
|
| Pharmacists | 3 | 2013 | 123 | 0.500 |
Why?
|
| Health Resources | 1 | 2016 | 88 | 0.500 |
Why?
|
| Anti-Anxiety Agents | 2 | 2008 | 31 | 0.500 |
Why?
|
| Police | 1 | 2016 | 36 | 0.490 |
Why?
|
| Treatment Outcome | 18 | 2024 | 5310 | 0.490 |
Why?
|
| Hepatitis C, Chronic | 2 | 2013 | 88 | 0.490 |
Why?
|
| Resource Allocation | 1 | 2015 | 19 | 0.480 |
Why?
|
| State Health Plans | 1 | 2015 | 10 | 0.480 |
Why?
|
| Health Care Rationing | 1 | 2015 | 21 | 0.480 |
Why?
|
| Cohort Studies | 18 | 2024 | 2378 | 0.480 |
Why?
|
| Social Stigma | 7 | 2025 | 64 | 0.480 |
Why?
|
| Prescriptions | 1 | 2015 | 31 | 0.480 |
Why?
|
| Longitudinal Studies | 10 | 2017 | 1189 | 0.480 |
Why?
|
| Mental Health Services | 7 | 2020 | 269 | 0.470 |
Why?
|
| Health Plan Implementation | 1 | 2015 | 40 | 0.470 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 60 | 0.470 |
Why?
|
| Community Mental Health Services | 1 | 2016 | 88 | 0.470 |
Why?
|
| Hindlimb | 4 | 2000 | 44 | 0.450 |
Why?
|
| Mental Disorders | 7 | 2019 | 723 | 0.450 |
Why?
|
| Evidence-Based Medicine | 3 | 2013 | 444 | 0.440 |
Why?
|
| Blood Loss, Surgical | 2 | 2012 | 58 | 0.440 |
Why?
|
| Syringes | 2 | 2024 | 11 | 0.440 |
Why?
|
| Directly Observed Therapy | 1 | 2013 | 3 | 0.430 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2000 | 15 | 0.430 |
Why?
|
| Prevalence | 11 | 2024 | 1258 | 0.430 |
Why?
|
| HIV Seronegativity | 4 | 2002 | 18 | 0.430 |
Why?
|
| Pharmaceutical Services | 2 | 2013 | 31 | 0.420 |
Why?
|
| Physicians, Family | 5 | 2008 | 75 | 0.420 |
Why?
|
| Adolescent | 16 | 2023 | 5862 | 0.420 |
Why?
|
| Patient Satisfaction | 3 | 2008 | 416 | 0.410 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 20 | 0.410 |
Why?
|
| Methamphetamine | 2 | 2023 | 22 | 0.410 |
Why?
|
| Internet | 2 | 2015 | 451 | 0.410 |
Why?
|
| Blood Transfusion | 2 | 2012 | 150 | 0.410 |
Why?
|
| Infant | 5 | 2021 | 1495 | 0.400 |
Why?
|
| Pilot Projects | 6 | 2022 | 919 | 0.400 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2012 | 9 | 0.400 |
Why?
|
| Residential Treatment | 3 | 2024 | 30 | 0.400 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 791 | 0.390 |
Why?
|
| Needles | 1 | 2013 | 65 | 0.390 |
Why?
|
| Health Personnel | 1 | 2016 | 343 | 0.390 |
Why?
|
| Length of Stay | 5 | 2007 | 786 | 0.390 |
Why?
|
| Prospective Studies | 15 | 2020 | 3076 | 0.390 |
Why?
|
| Age Factors | 5 | 2017 | 1507 | 0.380 |
Why?
|
| Logistic Models | 11 | 2019 | 1239 | 0.380 |
Why?
|
| Interviews as Topic | 7 | 2024 | 484 | 0.370 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 94 | 0.360 |
Why?
|
| Hematocrit | 2 | 2010 | 32 | 0.360 |
Why?
|
| Chronic Disease | 3 | 2010 | 719 | 0.350 |
Why?
|
| Comorbidity | 8 | 2019 | 1080 | 0.350 |
Why?
|
| Prescription Drugs | 1 | 2011 | 47 | 0.350 |
Why?
|
| Antiviral Agents | 3 | 2024 | 312 | 0.350 |
Why?
|
| Eye Diseases | 1 | 2011 | 35 | 0.350 |
Why?
|
| Pregnancy | 7 | 2021 | 2221 | 0.340 |
Why?
|
| Intraoperative Care | 1 | 2010 | 36 | 0.340 |
Why?
|
| Risk-Taking | 9 | 2013 | 158 | 0.340 |
Why?
|
| Rectal Neoplasms | 5 | 1996 | 98 | 0.330 |
Why?
|
| Violence | 2 | 2009 | 148 | 0.330 |
Why?
|
| Infant, Newborn | 6 | 2020 | 1287 | 0.330 |
Why?
|
| Alcoholic Intoxication | 2 | 2017 | 27 | 0.330 |
Why?
|
| Internship and Residency | 7 | 2002 | 752 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 707 | 0.320 |
Why?
|
| Quality of Health Care | 4 | 2012 | 514 | 0.320 |
Why?
|
| Psychiatry | 3 | 2005 | 114 | 0.320 |
Why?
|
| Leadership | 2 | 2023 | 194 | 0.310 |
Why?
|
| Influenza Vaccines | 2 | 2014 | 91 | 0.310 |
Why?
|
| Patient Care Team | 2 | 2024 | 330 | 0.310 |
Why?
|
| Neovascularization, Physiologic | 2 | 2000 | 101 | 0.310 |
Why?
|
| Databases, Factual | 4 | 2019 | 816 | 0.310 |
Why?
|
| Child, Preschool | 5 | 2023 | 1798 | 0.300 |
Why?
|
| Trazodone | 1 | 2008 | 3 | 0.300 |
Why?
|
| Recurrence | 5 | 2017 | 605 | 0.300 |
Why?
|
| Inpatients | 2 | 2024 | 292 | 0.300 |
Why?
|
| Evidence-Based Practice | 2 | 2023 | 79 | 0.290 |
Why?
|
| Health Care Surveys | 7 | 2013 | 279 | 0.290 |
Why?
|
| Education, Medical, Continuing | 2 | 2006 | 95 | 0.290 |
Why?
|
| Central Nervous System Depressants | 1 | 2008 | 42 | 0.290 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2008 | 17 | 0.290 |
Why?
|
| Regression Analysis | 8 | 2011 | 488 | 0.290 |
Why?
|
| Time Factors | 10 | 2017 | 3625 | 0.280 |
Why?
|
| Polycythemia | 1 | 2007 | 4 | 0.280 |
Why?
|
| Health Care Reform | 2 | 2019 | 85 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 678 | 0.280 |
Why?
|
| Program Evaluation | 5 | 2019 | 471 | 0.280 |
Why?
|
| Meningitis | 2 | 1998 | 18 | 0.270 |
Why?
|
| Ischemia | 4 | 2000 | 199 | 0.270 |
Why?
|
| Social Work | 2 | 2024 | 24 | 0.260 |
Why?
|
| Hallucinogens | 1 | 2006 | 14 | 0.260 |
Why?
|
| Pregnancy Complications | 3 | 2019 | 366 | 0.260 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2006 | 18 | 0.260 |
Why?
|
| Follow-Up Studies | 12 | 2017 | 2346 | 0.260 |
Why?
|
| Antidepressive Agents | 2 | 2010 | 213 | 0.260 |
Why?
|
| Outpatients | 3 | 2017 | 137 | 0.260 |
Why?
|
| Oxycodone | 1 | 2006 | 30 | 0.260 |
Why?
|
| Social Security | 1 | 2006 | 8 | 0.260 |
Why?
|
| Case Management | 2 | 2004 | 54 | 0.250 |
Why?
|
| Preventive Health Services | 3 | 2012 | 72 | 0.250 |
Why?
|
| Anemia | 1 | 2007 | 119 | 0.250 |
Why?
|
| Rehabilitation, Vocational | 1 | 2005 | 30 | 0.250 |
Why?
|
| Risk Factors | 16 | 2012 | 5005 | 0.250 |
Why?
|
| Internal Medicine | 5 | 2005 | 154 | 0.250 |
Why?
|
| Health Surveys | 3 | 2006 | 299 | 0.250 |
Why?
|
| Cocaine-Related Disorders | 1 | 2006 | 82 | 0.240 |
Why?
|
| Patient Selection | 4 | 2024 | 466 | 0.240 |
Why?
|
| Ethanol | 1 | 2008 | 309 | 0.240 |
Why?
|
| Drug Utilization | 2 | 2005 | 208 | 0.240 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2014 | 519 | 0.240 |
Why?
|
| Health Services for the Aged | 2 | 2004 | 47 | 0.230 |
Why?
|
| Mobile Health Units | 1 | 2024 | 10 | 0.230 |
Why?
|
| Surgery Department, Hospital | 2 | 1998 | 20 | 0.230 |
Why?
|
| Hospitals, Community | 2 | 2019 | 69 | 0.230 |
Why?
|
| Odds Ratio | 7 | 2014 | 748 | 0.220 |
Why?
|
| Motivational Interviewing | 2 | 2022 | 42 | 0.220 |
Why?
|
| Sex Factors | 7 | 2013 | 939 | 0.220 |
Why?
|
| Comprehensive Health Care | 1 | 2004 | 17 | 0.220 |
Why?
|
| Child | 4 | 2021 | 4209 | 0.220 |
Why?
|
| Sex Work | 1 | 2023 | 21 | 0.220 |
Why?
|
| Disabled Persons | 1 | 2006 | 189 | 0.210 |
Why?
|
| Health Behavior | 3 | 2002 | 452 | 0.210 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2023 | 89 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2025 | 144 | 0.210 |
Why?
|
| Seroepidemiologic Studies | 2 | 2023 | 48 | 0.210 |
Why?
|
| Sexual and Gender Minorities | 1 | 2025 | 70 | 0.210 |
Why?
|
| Medically Uninsured | 2 | 2019 | 39 | 0.210 |
Why?
|
| Mental Processes | 1 | 2023 | 18 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2012 | 808 | 0.210 |
Why?
|
| Vascular Surgical Procedures | 4 | 1993 | 252 | 0.200 |
Why?
|
| Connecticut | 2 | 2013 | 86 | 0.200 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 62 | 0.200 |
Why?
|
| Preoperative Care | 4 | 2007 | 180 | 0.200 |
Why?
|
| Federal Government | 2 | 2017 | 19 | 0.200 |
Why?
|
| Drug Utilization Review | 2 | 1999 | 52 | 0.190 |
Why?
|
| Prescription Drug Diversion | 1 | 2022 | 7 | 0.190 |
Why?
|
| Mandatory Reporting | 1 | 2002 | 18 | 0.190 |
Why?
|
| Friends | 1 | 2022 | 29 | 0.190 |
Why?
|
| Influenza, Human | 1 | 2004 | 193 | 0.190 |
Why?
|
| Domestic Violence | 1 | 2002 | 38 | 0.190 |
Why?
|
| Vaccination | 1 | 2004 | 335 | 0.190 |
Why?
|
| Safe Sex | 1 | 2001 | 25 | 0.190 |
Why?
|
| Binge Drinking | 1 | 2021 | 27 | 0.180 |
Why?
|
| Transportation of Patients | 1 | 2001 | 42 | 0.180 |
Why?
|
| Guideline Adherence | 4 | 2014 | 296 | 0.180 |
Why?
|
| Hospitals, Teaching | 3 | 2002 | 101 | 0.180 |
Why?
|
| Activities of Daily Living | 2 | 1999 | 288 | 0.180 |
Why?
|
| Health Services Research | 4 | 2013 | 266 | 0.180 |
Why?
|
| Medical History Taking | 1 | 2001 | 65 | 0.180 |
Why?
|
| Endarterectomy | 4 | 1989 | 18 | 0.170 |
Why?
|
| Coercion | 2 | 2016 | 58 | 0.170 |
Why?
|
| Smoking | 3 | 2014 | 825 | 0.170 |
Why?
|
| Guilt | 1 | 2020 | 6 | 0.170 |
Why?
|
| Shame | 1 | 2020 | 8 | 0.170 |
Why?
|
| Linear Models | 5 | 2012 | 403 | 0.170 |
Why?
|
| Cocaine | 4 | 2012 | 99 | 0.170 |
Why?
|
| Feasibility Studies | 5 | 2013 | 528 | 0.170 |
Why?
|
| Hospitals, Veterans | 2 | 2012 | 159 | 0.170 |
Why?
|
| Mortality | 1 | 2001 | 156 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2001 | 187 | 0.170 |
Why?
|
| Judgment | 1 | 2020 | 34 | 0.160 |
Why?
|
| Sickness Impact Profile | 1 | 1999 | 46 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 1 | 2000 | 101 | 0.160 |
Why?
|
| Health Equity | 1 | 2020 | 42 | 0.160 |
Why?
|
| Emergencies | 2 | 1999 | 111 | 0.160 |
Why?
|
| Vermont | 1 | 2019 | 16 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 1099 | 0.160 |
Why?
|
| Cost Allocation | 1 | 2019 | 3 | 0.160 |
Why?
|
| New Hampshire | 1 | 2019 | 43 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2011 | 1928 | 0.160 |
Why?
|
| Graft Survival | 2 | 2017 | 290 | 0.160 |
Why?
|
| Statistics as Topic | 4 | 2014 | 146 | 0.160 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 127 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2021 | 189 | 0.160 |
Why?
|
| Carotid Arteries | 2 | 1989 | 62 | 0.150 |
Why?
|
| Medication Errors | 1 | 1999 | 109 | 0.150 |
Why?
|
| Pandemics | 2 | 2021 | 617 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 32 | 0.150 |
Why?
|
| Analysis of Variance | 8 | 2008 | 591 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 1995 | 68 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 2 | 2024 | 63 | 0.150 |
Why?
|
| Communication | 2 | 2023 | 547 | 0.150 |
Why?
|
| Maternal Health Services | 1 | 2019 | 63 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 166 | 0.150 |
Why?
|
| Focus Groups | 1 | 2020 | 288 | 0.150 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 3 | 2013 | 25 | 0.150 |
Why?
|
| Decision Making | 2 | 2019 | 395 | 0.150 |
Why?
|
| Interprofessional Relations | 2 | 2012 | 130 | 0.150 |
Why?
|
| Health Insurance Exchanges | 1 | 2017 | 1 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 88 | 0.150 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 1998 | 10 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 146 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2020 | 144 | 0.140 |
Why?
|
| Transportation | 3 | 2024 | 32 | 0.140 |
Why?
|
| Risk Management | 1 | 1998 | 38 | 0.140 |
Why?
|
| Psychotic Disorders | 2 | 2012 | 149 | 0.140 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 250 | 0.140 |
Why?
|
| Public Policy | 1 | 2018 | 37 | 0.140 |
Why?
|
| Cardiology | 2 | 1997 | 163 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1998 | 190 | 0.140 |
Why?
|
| Polytetrafluoroethylene | 1 | 1997 | 18 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2014 | 142 | 0.140 |
Why?
|
| Patient Participation | 1 | 2019 | 216 | 0.140 |
Why?
|
| Patient Preference | 1 | 2018 | 78 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 192 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 205 | 0.140 |
Why?
|
| Donor Selection | 1 | 2017 | 16 | 0.140 |
Why?
|
| Survival Rate | 3 | 2019 | 802 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 1999 | 230 | 0.140 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1997 | 43 | 0.140 |
Why?
|
| Schizophrenia | 2 | 2012 | 247 | 0.140 |
Why?
|
| Urban Population | 7 | 2008 | 180 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 1999 | 354 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2017 | 30 | 0.130 |
Why?
|
| Physician's Role | 1 | 1998 | 120 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 1998 | 111 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2001 | 421 | 0.130 |
Why?
|
| Bipolar Disorder | 2 | 2012 | 243 | 0.130 |
Why?
|
| Organizational Innovation | 1 | 2017 | 80 | 0.130 |
Why?
|
| Cross Infection | 1 | 1998 | 152 | 0.130 |
Why?
|
| Diabetic Angiopathies | 3 | 2009 | 24 | 0.130 |
Why?
|
| Incidence | 5 | 2011 | 1241 | 0.130 |
Why?
|
| Chicago | 3 | 2001 | 26 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2017 | 136 | 0.130 |
Why?
|
| Organizations | 1 | 2016 | 6 | 0.130 |
Why?
|
| Social Support | 2 | 2013 | 355 | 0.130 |
Why?
|
| Postoperative Care | 1 | 1996 | 116 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 1997 | 141 | 0.130 |
Why?
|
| Human Experimentation | 1 | 2016 | 32 | 0.120 |
Why?
|
| Diabetes Complications | 2 | 2011 | 101 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 1997 | 189 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 299 | 0.120 |
Why?
|
| Contract Services | 1 | 2015 | 2 | 0.120 |
Why?
|
| Patient Education as Topic | 3 | 2014 | 454 | 0.120 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.120 |
Why?
|
| Endarterectomy, Carotid | 1 | 1996 | 91 | 0.120 |
Why?
|
| Risk Reduction Behavior | 2 | 2006 | 121 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 1995 | 137 | 0.120 |
Why?
|
| Methylprednisolone | 1 | 1995 | 32 | 0.120 |
Why?
|
| Body Weight | 1 | 2017 | 370 | 0.120 |
Why?
|
| Intersectoral Collaboration | 1 | 2015 | 17 | 0.120 |
Why?
|
| Carcinoma | 2 | 1987 | 116 | 0.120 |
Why?
|
| Spinal Cord Injuries | 1 | 1995 | 38 | 0.120 |
Why?
|
| Community-Institutional Relations | 1 | 2015 | 37 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2012 | 555 | 0.120 |
Why?
|
| Safety-net Providers | 1 | 2015 | 30 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 1 | 1995 | 67 | 0.120 |
Why?
|
| Taurine | 1 | 2014 | 5 | 0.120 |
Why?
|
| Disulfiram | 1 | 2014 | 5 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 1996 | 138 | 0.110 |
Why?
|
| Pneumococcal Vaccines | 1 | 2014 | 19 | 0.110 |
Why?
|
| Directive Counseling | 1 | 2014 | 38 | 0.110 |
Why?
|
| Elective Surgical Procedures | 2 | 2022 | 114 | 0.110 |
Why?
|
| Aftercare | 2 | 2022 | 71 | 0.110 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 314 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 439 | 0.110 |
Why?
|
| Spinal Cord | 1 | 1995 | 194 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 691 | 0.110 |
Why?
|
| Smoking Prevention | 2 | 2013 | 158 | 0.110 |
Why?
|
| Housing | 2 | 2024 | 72 | 0.110 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 64 | 0.110 |
Why?
|
| Smoke-Free Policy | 1 | 2013 | 9 | 0.110 |
Why?
|
| Accountable Care Organizations | 1 | 2015 | 66 | 0.110 |
Why?
|
| Staff Development | 2 | 2007 | 55 | 0.110 |
Why?
|
| History, 19th Century | 3 | 2001 | 43 | 0.110 |
Why?
|
| Tobacco Products | 1 | 2014 | 71 | 0.110 |
Why?
|
| Ribavirin | 1 | 2013 | 24 | 0.110 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2013 | 3 | 0.110 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 55 | 0.100 |
Why?
|
| Personal Autonomy | 1 | 2013 | 68 | 0.100 |
Why?
|
| Interferon-alpha | 1 | 2013 | 99 | 0.100 |
Why?
|
| Viral Load | 1 | 2013 | 220 | 0.100 |
Why?
|
| Collateral Circulation | 1 | 1992 | 22 | 0.100 |
Why?
|
| History, 20th Century | 3 | 2001 | 224 | 0.100 |
Why?
|
| Electronic Prescribing | 1 | 2012 | 11 | 0.100 |
Why?
|
| Physician-Patient Relations | 3 | 2002 | 399 | 0.100 |
Why?
|
| Specialization | 2 | 2005 | 78 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 165 | 0.100 |
Why?
|
| Program Development | 3 | 2008 | 203 | 0.100 |
Why?
|
| Total Quality Management | 1 | 1992 | 56 | 0.090 |
Why?
|
| Blood Coagulation | 1 | 2012 | 37 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2013 | 354 | 0.090 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2011 | 3 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 1996 | 432 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 210 | 0.090 |
Why?
|
| Lacerations | 1 | 2011 | 15 | 0.090 |
Why?
|
| Interview, Psychological | 2 | 2009 | 74 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2014 | 848 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 1565 | 0.090 |
Why?
|
| Mandatory Programs | 1 | 2011 | 17 | 0.090 |
Why?
|
| Tuberculosis | 3 | 2000 | 270 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 1988 | 323 | 0.090 |
Why?
|
| Vitreous Body | 1 | 2011 | 30 | 0.090 |
Why?
|
| Cataract | 1 | 2011 | 51 | 0.090 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 118 | 0.090 |
Why?
|
| Accreditation | 2 | 2007 | 73 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2012 | 137 | 0.090 |
Why?
|
| Hospital Departments | 1 | 1990 | 12 | 0.090 |
Why?
|
| Crack Cocaine | 3 | 1997 | 7 | 0.090 |
Why?
|
| Streptonigrin | 1 | 2010 | 3 | 0.090 |
Why?
|
| Hospitals, University | 2 | 2001 | 53 | 0.090 |
Why?
|
| Erectile Dysfunction | 1 | 2010 | 23 | 0.090 |
Why?
|
| Heart Failure | 2 | 2014 | 857 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 742 | 0.090 |
Why?
|
| Citalopram | 1 | 2010 | 19 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2010 | 131 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 166 | 0.080 |
Why?
|
| Medicine | 1 | 1990 | 57 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2010 | 714 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 939 | 0.080 |
Why?
|
| Testosterone | 1 | 2010 | 114 | 0.080 |
Why?
|
| Patient Discharge | 2 | 2025 | 493 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 284 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 217 | 0.080 |
Why?
|
| Tuberculin Test | 2 | 2000 | 9 | 0.080 |
Why?
|
| Models, Organizational | 3 | 2015 | 92 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 1990 | 150 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2010 | 177 | 0.080 |
Why?
|
| Unsafe Sex | 1 | 2009 | 27 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2009 | 55 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2012 | 674 | 0.080 |
Why?
|
| Hemodynamics | 1 | 1990 | 231 | 0.080 |
Why?
|
| Skin | 3 | 2006 | 357 | 0.080 |
Why?
|
| Inactivation, Metabolic | 1 | 2008 | 14 | 0.080 |
Why?
|
| Macular Degeneration | 1 | 2011 | 178 | 0.070 |
Why?
|
| New York City | 9 | 2000 | 76 | 0.070 |
Why?
|
| Internal-External Control | 1 | 2008 | 31 | 0.070 |
Why?
|
| Verbal Behavior | 1 | 2008 | 36 | 0.070 |
Why?
|
| Antisocial Personality Disorder | 1 | 2008 | 34 | 0.070 |
Why?
|
| AIDS Serodiagnosis | 2 | 2002 | 19 | 0.070 |
Why?
|
| HIV Seroprevalence | 3 | 1996 | 7 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2001 | 339 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 1988 | 62 | 0.070 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 2 | 2000 | 4 | 0.070 |
Why?
|
| Intestine, Large | 1 | 1987 | 5 | 0.070 |
Why?
|
| Life Tables | 2 | 1997 | 23 | 0.070 |
Why?
|
| Cost Control | 1 | 2007 | 24 | 0.070 |
Why?
|
| Community Networks | 1 | 2007 | 30 | 0.070 |
Why?
|
| Clinical Competence | 3 | 2002 | 686 | 0.070 |
Why?
|
| Drug Prescriptions | 2 | 2006 | 168 | 0.070 |
Why?
|
| Professional Practice | 1 | 2006 | 22 | 0.070 |
Why?
|
| Educational Status | 1 | 2008 | 264 | 0.070 |
Why?
|
| Risk | 1 | 2007 | 364 | 0.070 |
Why?
|
| Rabbits | 2 | 2000 | 326 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2011 | 242 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2012 | 116 | 0.060 |
Why?
|
| Medical Records | 1 | 2006 | 133 | 0.060 |
Why?
|
| Organizational Culture | 1 | 2007 | 106 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 191 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 36 | 0.060 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2006 | 8 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2006 | 35 | 0.060 |
Why?
|
| Confidentiality | 2 | 2003 | 52 | 0.060 |
Why?
|
| Cues | 1 | 2006 | 73 | 0.060 |
Why?
|
| Medical Audit | 1 | 2006 | 58 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2008 | 279 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2006 | 45 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1998 | 574 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 397 | 0.060 |
Why?
|
| Depression | 2 | 2010 | 831 | 0.060 |
Why?
|
| Sleep Stages | 1 | 2005 | 16 | 0.060 |
Why?
|
| Injections | 2 | 2018 | 76 | 0.060 |
Why?
|
| Women's Health | 1 | 2008 | 360 | 0.060 |
Why?
|
| Specialties, Surgical | 2 | 1999 | 45 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1976 | 72 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2005 | 15 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2005 | 39 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2006 | 199 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2009 | 79 | 0.060 |
Why?
|
| Epidermolysis Bullosa | 1 | 2004 | 10 | 0.060 |
Why?
|
| Gynecology | 2 | 2005 | 50 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2000 | 678 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2005 | 26 | 0.060 |
Why?
|
| Cannabinoids | 1 | 2005 | 38 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 1996 | 300 | 0.060 |
Why?
|
| Gender Identity | 1 | 2025 | 62 | 0.060 |
Why?
|
| Femoral Artery | 3 | 1988 | 103 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2005 | 52 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2024 | 66 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 1 | 2024 | 8 | 0.060 |
Why?
|
| Popliteal Artery | 2 | 1976 | 26 | 0.060 |
Why?
|
| Cannabis | 1 | 2005 | 51 | 0.050 |
Why?
|
| Decision Trees | 1 | 2003 | 51 | 0.050 |
Why?
|
| Obstetrics | 2 | 2005 | 80 | 0.050 |
Why?
|
| Uncompensated Care | 1 | 2003 | 5 | 0.050 |
Why?
|
| Refusal to Treat | 1 | 2003 | 3 | 0.050 |
Why?
|
| Laboratories, Hospital | 1 | 2003 | 10 | 0.050 |
Why?
|
| Halfway Houses | 1 | 2003 | 2 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2003 | 76 | 0.050 |
Why?
|
| Schools, Medical | 2 | 2001 | 142 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2006 | 250 | 0.050 |
Why?
|
| Rats | 2 | 1998 | 1908 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2003 | 48 | 0.050 |
Why?
|
| Attitude | 1 | 2023 | 97 | 0.050 |
Why?
|
| Community Mental Health Centers | 1 | 2003 | 16 | 0.050 |
Why?
|
| Convalescence | 1 | 2003 | 18 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 636 | 0.050 |
Why?
|
| House Calls | 1 | 2023 | 18 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1486 | 0.050 |
Why?
|
| Occupational Health Services | 1 | 2003 | 36 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 275 | 0.050 |
Why?
|
| Phylogeny | 1 | 2024 | 337 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2003 | 88 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 278 | 0.050 |
Why?
|
| Grounded Theory | 1 | 2022 | 17 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2004 | 401 | 0.050 |
Why?
|
| Habits | 1 | 2022 | 20 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 237 | 0.050 |
Why?
|
| Parenting | 1 | 2023 | 67 | 0.050 |
Why?
|
| Interpersonal Relations | 2 | 2001 | 150 | 0.050 |
Why?
|
| Workplace | 1 | 2003 | 169 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2003 | 158 | 0.050 |
Why?
|
| Animals | 6 | 2000 | 19686 | 0.050 |
Why?
|
| Curriculum | 1 | 2005 | 564 | 0.050 |
Why?
|
| Crisis Intervention | 1 | 2002 | 26 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2002 | 133 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2001 | 43 | 0.050 |
Why?
|
| Episode of Care | 1 | 2001 | 8 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2001 | 15 | 0.050 |
Why?
|
| Poverty | 1 | 2003 | 283 | 0.040 |
Why?
|
| Genomics | 1 | 2024 | 322 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 310 | 0.040 |
Why?
|
| Specialty Boards | 2 | 1990 | 13 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 2 | 2013 | 98 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 1996 | 448 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2001 | 111 | 0.040 |
Why?
|
| Certification | 2 | 1990 | 46 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2000 | 108 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2002 | 192 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 2 | 2014 | 333 | 0.040 |
Why?
|
| Cardiac Rehabilitation | 1 | 2021 | 66 | 0.040 |
Why?
|
| Nurses | 1 | 2021 | 102 | 0.040 |
Why?
|
| Research Design | 3 | 2011 | 556 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 1999 | 20 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 1996 | 81 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 1999 | 34 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 1999 | 5 | 0.040 |
Why?
|
| Psychometrics | 2 | 2014 | 363 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 398 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2006 | 515 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 113 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 256 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2019 | 19 | 0.040 |
Why?
|
| Physicians | 2 | 2021 | 443 | 0.040 |
Why?
|
| Streptozocin | 1 | 1998 | 21 | 0.040 |
Why?
|
| Accidental Falls | 1 | 1999 | 125 | 0.040 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1998 | 8 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1998 | 68 | 0.040 |
Why?
|
| Self-Help Groups | 1 | 1998 | 37 | 0.040 |
Why?
|
| Income | 1 | 2019 | 157 | 0.040 |
Why?
|
| Forearm | 1 | 1997 | 19 | 0.040 |
Why?
|
| Residence Characteristics | 2 | 2015 | 215 | 0.030 |
Why?
|
| AIDS Vaccines | 1 | 1997 | 65 | 0.030 |
Why?
|
| Angiography | 2 | 1974 | 145 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1997 | 138 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 1995 | 2056 | 0.030 |
Why?
|
| Benchmarking | 1 | 1998 | 135 | 0.030 |
Why?
|
| Radioisotope Teletherapy | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cobalt Radioisotopes | 1 | 1996 | 5 | 0.030 |
Why?
|
| Spermatozoa | 1 | 1998 | 253 | 0.030 |
Why?
|
| Thailand | 5 | 1995 | 94 | 0.030 |
Why?
|
| Mental Health | 1 | 1999 | 336 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 319 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 1997 | 61 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 103 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1996 | 58 | 0.030 |
Why?
|
| Condoms | 2 | 1993 | 47 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1996 | 38 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1996 | 37 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1978 | 215 | 0.030 |
Why?
|
| Heroin | 2 | 1997 | 12 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1997 | 121 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 1995 | 5 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 1995 | 15 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 229 | 0.030 |
Why?
|
| Saphenous Vein | 2 | 1976 | 51 | 0.030 |
Why?
|
| Safety | 1 | 1996 | 141 | 0.030 |
Why?
|
| Economic Competition | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 1996 | 68 | 0.030 |
Why?
|
| Ownership | 1 | 2015 | 17 | 0.030 |
Why?
|
| Systems Integration | 1 | 2015 | 26 | 0.030 |
Why?
|
| Behavior | 1 | 1995 | 36 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1995 | 132 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 1998 | 1058 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1995 | 179 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 1995 | 76 | 0.030 |
Why?
|
| Coronary Disease | 1 | 1996 | 246 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 1995 | 133 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 2 | 1976 | 218 | 0.030 |
Why?
|
| Movement | 1 | 1995 | 149 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 1996 | 280 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1995 | 452 | 0.030 |
Why?
|
| Hospitals | 1 | 1997 | 379 | 0.030 |
Why?
|
| History, 18th Century | 1 | 1993 | 8 | 0.030 |
Why?
|
| History, Ancient | 1 | 1993 | 11 | 0.030 |
Why?
|
| Health Facility Administrators | 1 | 2013 | 7 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 275 | 0.030 |
Why?
|
| Didanosine | 1 | 1992 | 3 | 0.030 |
Why?
|
| Zidovudine | 1 | 1992 | 12 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 158 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 1993 | 66 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 1992 | 15 | 0.030 |
Why?
|
| Spectrophotometry | 1 | 1992 | 35 | 0.030 |
Why?
|
| Ligation | 1 | 1992 | 33 | 0.020 |
Why?
|
| Washington | 1 | 2012 | 24 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 257 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 93 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 146 | 0.020 |
Why?
|
| Prothrombin Time | 1 | 2012 | 6 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 9 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 342 | 0.020 |
Why?
|
| Contrast Media | 1 | 1974 | 406 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1985 | 74 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 70 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 57 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2012 | 93 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 93 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 1992 | 57 | 0.020 |
Why?
|
| Health Education | 2 | 2008 | 184 | 0.020 |
Why?
|
| Cardiac Output | 1 | 1990 | 27 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1990 | 26 | 0.020 |
Why?
|
| Hypertension | 1 | 1996 | 570 | 0.020 |
Why?
|
| Radiography | 1 | 1992 | 518 | 0.020 |
Why?
|
| Acute Disease | 1 | 1992 | 660 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 1990 | 48 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 1990 | 13 | 0.020 |
Why?
|
| Teaching | 1 | 1990 | 152 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 1990 | 68 | 0.020 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 1 | 2009 | 2 | 0.020 |
Why?
|
| Coumarins | 1 | 1988 | 6 | 0.020 |
Why?
|
| HIV-1 | 1 | 1994 | 692 | 0.020 |
Why?
|
| Educational Measurement | 1 | 1990 | 213 | 0.020 |
Why?
|
| Iodine Isotopes | 1 | 1968 | 2 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 1968 | 16 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1988 | 45 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1988 | 75 | 0.020 |
Why?
|
| Financial Support | 1 | 2008 | 5 | 0.020 |
Why?
|
| Necrosis | 1 | 1988 | 140 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 1034 | 0.020 |
Why?
|
| Psychology | 1 | 2008 | 44 | 0.020 |
Why?
|
| Renal Veins | 1 | 1987 | 6 | 0.020 |
Why?
|
| Heparin | 1 | 1988 | 111 | 0.020 |
Why?
|
| Pediatrics | 1 | 1990 | 241 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 169 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 301 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 1988 | 186 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2009 | 207 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1987 | 58 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 1987 | 6 | 0.020 |
Why?
|
| Health Promotion | 1 | 2011 | 471 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1988 | 104 | 0.020 |
Why?
|
| Arteriovenous Fistula | 1 | 1987 | 41 | 0.020 |
Why?
|
| Colostomy | 1 | 1987 | 23 | 0.020 |
Why?
|
| Universities | 1 | 2008 | 144 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1987 | 93 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 13 | 0.020 |
Why?
|
| England | 1 | 2006 | 24 | 0.020 |
Why?
|
| Lactones | 1 | 2006 | 24 | 0.020 |
Why?
|
| Sulfones | 1 | 2006 | 36 | 0.020 |
Why?
|
| Students | 1 | 2008 | 202 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 71 | 0.020 |
Why?
|
| Dogs | 1 | 1987 | 316 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 102 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2006 | 65 | 0.020 |
Why?
|
| Pyridines | 1 | 2006 | 98 | 0.010 |
Why?
|
| Permissiveness | 1 | 2005 | 1 | 0.010 |
Why?
|
| Leg | 2 | 1976 | 86 | 0.010 |
Why?
|
| American Heart Association | 1 | 2006 | 122 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2006 | 120 | 0.010 |
Why?
|
| Morals | 1 | 2005 | 21 | 0.010 |
Why?
|
| Bowen's Disease | 1 | 2004 | 1 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1985 | 61 | 0.010 |
Why?
|
| Brazil | 2 | 1995 | 88 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 107 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 129 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 127 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 497 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 833 | 0.010 |
Why?
|
| Information Services | 1 | 2002 | 34 | 0.010 |
Why?
|
| Social Perception | 1 | 2002 | 38 | 0.010 |
Why?
|
| Boston | 1 | 2002 | 247 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1309 | 0.010 |
Why?
|
| Learning | 1 | 2000 | 172 | 0.010 |
Why?
|
| Sigmoid Neoplasms | 1 | 1978 | 2 | 0.010 |
Why?
|
| Illinois | 1 | 1997 | 12 | 0.010 |
Why?
|
| Skin Tests | 1 | 1997 | 20 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1997 | 23 | 0.010 |
Why?
|
| World Health Organization | 1 | 1996 | 30 | 0.010 |
Why?
|
| Marijuana Smoking | 1 | 1997 | 17 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1995 | 25 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1976 | 119 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1976 | 223 | 0.010 |
Why?
|
| Scotland | 1 | 1995 | 8 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1995 | 33 | 0.010 |
Why?
|
| Fever | 1 | 1995 | 63 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1976 | 291 | 0.010 |
Why?
|
| Self-Assessment | 1 | 1994 | 60 | 0.010 |
Why?
|
| Personality Development | 1 | 1993 | 6 | 0.010 |
Why?
|
| Child Abuse, Sexual | 1 | 1993 | 25 | 0.010 |
Why?
|
| Child of Impaired Parents | 1 | 1993 | 23 | 0.010 |
Why?
|
| Dangerous Behavior | 1 | 1993 | 28 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 40 | 0.010 |
Why?
|
| Rehabilitation | 1 | 1991 | 6 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1995 | 391 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1972 | 211 | 0.010 |
Why?
|
| Contraception | 1 | 1992 | 68 | 0.010 |
Why?
|
| Prenatal Care | 1 | 1993 | 171 | 0.010 |
Why?
|
| Polymers | 1 | 1972 | 316 | 0.000 |
Why?
|
| Aorta, Thoracic | 1 | 1988 | 81 | 0.000 |
Why?
|
| Intermittent Claudication | 1 | 1988 | 53 | 0.000 |
Why?
|
| Aorta | 1 | 1988 | 108 | 0.000 |
Why?
|
| Hypothyroidism | 1 | 1968 | 39 | 0.000 |
Why?
|
| Aortic Aneurysm | 1 | 1987 | 81 | 0.000 |
Why?
|